Accumulating evidence suggests that C-type lectin-like receptor-2 (CLEC-2) plays an important role in atherothrombosis.In this case-control study,we investigated the association between CLEC-2 and incidence of coronary artery disease (CAD).A total of 216 patients,including 14 cases of stable angina pectoris (SAP,non-ACS) and 202 cases of acute coronary syndrome (ACS),and 89 non-CAD control subjects were enrolled.Plasma levels of soluble CLEC-2 (sCLEC-2) were measured using the enzyme-linked immunosorbent assay (ELISA).Compared with the control group (65.69 (55.36-143.22) pg/mL),the plasma levels of sCLEC-2 were significantly increased in patients with CAD (133.67 (88.76-220.09) pg/mL) and ACS (134.16 (88.88-225.81) pg/mL).The multivariate adjusted odds ratios (95％ confidence interval) of CAD reached 2.01 (1.52-2.66) (Ptrend ＜ 0.001) for each 1-quartile increase in sCLEC-2.Restricted cubic splines showed a positive dose-response association between sCLEC2 and CAD incidence (Plinearity ＜ 0.001).The addition of sCLEC-2 to conventional risk factors improved the C statistic (0.821 vs.0.761,P =0.004) and reclassification ability (net reclassification improvement:57.45％,P ＜ 0.001;integrated discrimination improvement:8.27％,P ＜ 0.001) for CAD.In conclusion,high plasma sCLEC-2 is independently associated with CAD risk,and the prognostic value of sCLEC-2 may be evaluated in future prospective studies.